Pipeline

Vernalis entered into a development and licensing deal with Tris Pharma, Inc, in February 2012, obtaining exclusive rights to Tris’ extended-release technology for use in the US prescription cough cold market with approximately 30-35 million prescriptions annually, it is potentially worth over $3 billion at 2015 brand pricing. 

In October 2015, Vernalis also acquired the US rights to Moxatag®, a once-a-day amoxicillin for strep throat in adult and pediatric patients 12 years of age or older.

To see the status of these programmes at a glance – roll over any listing or click on it to find out more.

 

 

Click here for more details on Tuzistra® XR, (codeine polistirex and chlorpheniramine polistirex) extended-release oral suspension, CIII (DEA Schedule III), the full US Prescribing Information including Boxed Warning and Medication Guide.

Click here for more details on Moxatag® and including full US Prescribing Information.

Latest News

AGM Statement

Vernalis plc ("Vernalis" or the "Company") provides an update ahead of its Annual General Meeting ("AGM") being held today at 10.30 am at the offices of Covington & Burling, 265 Strand, London WC2R 1BH.

Read more ...

Fact Sheet

For more information on Vernalis, click below to download a copy of our fact sheet

 

Factsheet-Nov14

 

 

 

 

Contact Vernalis Therapeutics

T: 1-484-913-0700
F: 1-610-651 5976

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch